Image credit: Boston Magazine

Research coming out of Brigham and Women’s Hospital (BWH) may prove that one drug could potentially reduce the chance of three great health risks. Originally, Paul Ridker, Director of the Center for Cardiovascular Disease Prevention at BWH, and his team of researchers set out to see if canakinumab—an anti-inflammatory drug—could decrease recurring heart problems in patients who've previously suffered from a heart attack. What they discovered was even more impressive.

Not only do the results seem to confirm the hypothesis, but participants taking canakinumab also saw lowered rates of lung cancer mortality and stroke—all by lowering inflammation in the body. This discovery comes after 25 years of research led by Ridker, who says that this is "cracking the door open on the third era" in preventive cardiology.

Read the entire article here.

Topics: Innovation, Academic Medical Centers

View all Topics View Archives